Search

everythinglearnresearchcommunity

for

Search:↓

RU58841, combined with 5% minoxidil, helped reduce acne and hair loss. Users discussed using RU58841 cream for acne and shared experiences with other treatments like finasteride and dutasteride.

Taurine shows potential in combating hair loss caused by chemical stress, especially when combined with other treatments like finasteride. Finasteride demonstrated better stress-reducing effects in the study.

Kintor Pharmaceutical's new hair loss treatment, KX-826, is entering the market. Users are eager to see its effectiveness before celebrating.

The conversation discusses the potential of Replicel/Shiseido treatment for hair loss, questioning its effectiveness, whether it grows new follicles, and its market release timeline. It also compares Replicel to other competitors like Kyocera/RIKEN/Tsuji.

RU58841, Minoxidil, and finasteride are discussed as treatments for hair loss. RU58841 is highlighted for its potential effectiveness.

The user is experiencing hair regrowth using finasteride, minoxidil, and KX-826. They regret not starting treatment earlier but are now seeing progress.

The conversation discusses hair loss and the ineffectiveness of a treatment called pyrilutamide, with one user experiencing negative results and questioning the product's authenticity.

Han Bio plans to start Phase 1 clinical trials for a hair growth treatment in 2027 after successful results in mice. Many users express skepticism about the effectiveness of treatments that work on mice but not on humans, and discuss existing treatments like finasteride and minoxidil.

The user reports improvement in temple hair after three weeks of using finasteride, minoxidil, ketoconazole, microneedling, stemoxydine, and follicopeptide. They note visible progress by maintaining the same hair length for comparison.

Pyrilutamide shows minimal systemic absorption with low plasma levels and no accumulation, suggesting it's unlikely to cause systemic side effects. However, full results are not yet published in scientific journals.

My hairline, I am only 23. This conversation is about a user's experience with treatments for androgenic alopecia, including finasteride, dutasteride, RU, minoxidil, progesterone, melatonin, LLLT, oral minoxidil, and Pyrilutamide. They have tried many treatments over the course of two years without seeing much success, and they are considering getting a hair system as a last resort.

Dr. Tsuji is giving online lectures about hair multiplication trials. Users express hope for a cure, but some are skeptical about its timeline.

The conversation discusses using NAC and quercetin as supplements for hair loss, with some users also mentioning finasteride. NAC is highlighted for its potential benefits, but concerns about its safety and absorption are also raised.

Treatments for hair loss, such as Minoxidil, Finasteride and RU58841, as well as using serrapeptase to break up scar tissue in the scalp.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

Kintor's 1% Pyrilutamide will be released in October/November. The user cannot tolerate finasteride.

The conversation discusses hair regrowth progress using finasteride, minoxidil, dutasteride, ketoconazole, microneedling, and multivitamins. The user shares their journey and receives advice on haircuts and additional treatments like PRP and RU58841.

The user healthydudenextdoor starting a new topical anti-androgen hair loss treatment, Pyrilutamide, and discussing their current regimen of finasteride and minoxidil.

HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

First people receive Pyrilutamide on March 19th, 2022 for hair loss treatment. Users discuss obtaining the drug, its patent, and potential group buys.

The user is seeking recommendations for topical saw palmetto and pumpkin seed oil products to treat early male pattern baldness and is considering different options available online. They are specifically asking which saw palmetto product to choose between two provided links.

The user is experiencing irritation from using PG with RU58841 and is seeking alternative solutions like K&B in the UK. They report redness, itchiness, and flaky skin from the current treatment.

A user's successful hair regrowth journey using a cocktail of finasteride, minoxidil, and ketoconazole. The user started seeing noticeable results after 8 months and also incorporated saw palmetto, biotin, keratin, and dermarolling into their routine.

The conversation discusses Shiseido's RepliCel Hair-01 technology for hair regeneration, which aims to stop hair loss with minimal regrowth. Treatments mentioned include Minoxidil, finasteride, and RU58841.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.

The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It suggests that affordable genetic therapy could be the ultimate solution.

The post discusses a new hair loss treatment involving an improved pyri formula that has shown promising results, including thicker hair and a restored hairline, with minimal side effects. The author seeks investors to collaborate with Kintor or acquire the pyri patent, offering equity rewards and complimentary samples for verification.

Breezula's phase 3 results are expected soon, but its release is likely delayed until 2027 or 2028. The discussion highlights the need for more hair growth stimulants like AMP-303 and PP-405, as current treatments like Dutasteride effectively stop hair loss but don't regrow hair.

The user is using RU58841 twice daily, dutasteride 0.5mg every two days, dutasteride mesotherapy every three months, and 20mg oral minoxidil daily. Other users suggest this regimen is excessive and recommend adding microneedling and ketoconazole shampoo.